E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Gastroesophageal Adenocarcinoma (GEA) |
Adenocarcinoma gastroesofágico (AGE) |
|
E.1.1.1 | Medical condition in easily understood language |
Gastroesophageal Adenocarcinoma (GEA) |
Adenocarcinoma gastroesofágico (AGE) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 22.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10082464 |
E.1.2 | Term | Advanced gastric carcinoma |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10055458 |
E.1.2 | Term | Esophageal adenocarcinoma |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
●To compare the efficacy of zanidatamab in combination with chemotherapy or in combination with chemotherapy and tislelizumab to the efficacy of trastuzumab in combination with chemotherapy in subjects with unresectable locally advanced, recurrent or metastatic HER2 positive GEA |
Comparar la eficacia de zanidatamab en combinación con quimioterapia o en combinación con quimioterapia y tislelizumab con la eficacia de trastuzumab en combinación con quimioterapia en sujetos con AGE positivo para HER2 localmente avanzado, recurrente o metastásico irresecable. |
|
E.2.2 | Secondary objectives of the trial |
●To further compare the efficacy of zanidatamab in combination with chemotherapy or chemotherapy and tislelizumab to chemotherapy with trastuzumab ●To evaluate the safety and tolerability of zanidatamab in combination with chemotherapy or chemotherapy and tislelizumab ●To evaluate the effect of zanidatamab in combination with chemotherapy or chemotherapy and tislelizumab on health-related quality of life (HRQoL) ●To evaluate the pharmacokinetics (PK) of zanidatamab in combination with chemotherapy or chemotherapy and tislelizumab ●To evaluate the PK of tislelizumab in combination with chemotherapy and zanidatamab ●To evaluate the immunogenicity of zanidatamab in combination with chemotherapy or chemotherapy and tislelizumab ●To evaluate the immunogenicity of tislelizumab in combination with chemotherapy and zanidatamab |
- Comparar mejor la eficacia de zanidatamab en combinación con quimioterapia o quimioterapia y tislelizumab con la de quimioterapia con trastuzumab - Evaluar la seguridad y la tolerabilidad de zanidatamab en combinación con quimioterapia o quimioterapia y tislelizumab. - Evaluar el efecto de zanidatamab en combinación con quimioterapia o quimioterapia y tislelizumab en la calidad de vida relacionada con la salud (CVRS). - Evaluar la farmacocinética (FC) de zanidatamab en combinación con quimioterapia o quimioterapia y tislelizumab. - Evaluar la FC de tislelizumab en combinación con quimioterapia y zanidatamab. - Evaluar la inmunogenicidad de zanidatamab en combinación con quimioterapia o quimioterapia y tislelizumab. - Evaluar la inmunogenicidad de tislelizumab en combinación con quimioterapia y zanidatamab. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1.Histologically confirmed unresectable locally advanced, recurrent or metastatic HER2-positive gastroesophageal adenocarcinoma (adenocarcinomas of the stomach or esophagus, including the gastroesophageal junction), defined as 3+ HER2 expression by IHC or 2+ HER2 expression by IHC with ISHpositivity per central assessment. Subjects with esophageal adenocarcinoma must not be eligible for combined chemoradiotherapy at the time of enrollment. 2.Assessable (measurable or non-measurable) disease as defined by RECIST 1.1. 3.Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, assessed within 3 days prior to randomization 4.Adequate organ function 5.Left ventricular ejection fraction (LVEF) ≥ 50% as determined by either echocardiogram or multiple gated acquisition scan (MUGA) |
1. Adenocarcinoma gastroesofágico positivo para HER2, localmente avanzado irresecable, recurrente o metastásico confirmado histológicamente (adenocarcinomas de estómago o esófago, incluida la unión gastroesofágica), definido como una expresión de 3+ de HER2 mediante IHQ o una expresión de 2+ de HER2 mediante IHQ con positividad de ISH según una evaluación centralizada. Los sujetos con adenocarcinoma esofágico no podrán optar a la quimiorradioterapia combinada en el momento de inclusión. 2. Enfermedad evaluable (medible o no medible) conforme a los criterios RECIST 1.1. 3. Estado funcional del Eastern Cooperative Oncology Group (ECOG) de 0 o 1, evaluado en los 3 días previos a la aleatorización. 4. Función hepática adecuada 5. Fracción de eyección del ventrículo izquierdo (FEVI) >= 50% determinada mediante ecocardiograma o ventriculografía isotópica en equilibrio (MUGA) |
|
E.4 | Principal exclusion criteria |
1.Prior treatment with a HER2-targeted agent, with the exception of subjects who received HER2-targeted treatment for breast cancer > 5 years prior to initial diagnosis of GEA. 2.Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2 or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways. 3.Untreated central nervous system (CNS) metastases, symptomatic CNS metastases, or radiation treatment for CNS metastases within 4 weeks prior to randomization. Stable, treated brain metastases are allowed (defined as subjects who are off steroids and anticonvulsants and are neurologically stable with no evidence of radiographic progression for at least 4 weeks prior to randomization). 4.Known history of or ongoing leptomeningeal disease (LMD). 5.Prior or concurrent invasive malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen. 6.Known active hepatitis 7.Any history of human immunodeficiency virus (HIV) infection 8.Known SARS-CoV-2 infection; subjects with prior infection that has resolved per local institutions’ requirements and screening guidance are eligible 9.Clinically significant cardiac disease, such as ventricular arrhythmia requiring therapy, uncontrolled hypertension or any history of symptomatic congestive heart failure (CHF). 10.QTc Fridericia (QTcF) > 470 ms. 11.Ongoing Grade 2 or greater peripheral neuropathy |
1. Tratamiento previo con un fármaco dirigido contra HER2, con la excepción de las pacientes que hayan recibido tratamiento dirigido contra HER2 para el cáncer de mama > 5 años antes del diagnóstico inicial de AGE. 2. Tratamiento previo con anticuerpos anti-PD-1, anti-PD-L1 y anti-PDL2 o cualquier otro anticuerpo o fármaco que actúe específicamente sobre la coestimulación de linfocitos T o vías de puntos de control inmunológico. 3. Metástasis en el sistema nervioso central (SNC) no tratadas, metástasis sintomáticas en el SNC o radioterapia para metástasis en el SNC en las 4 semanas anteriores a la aleatorización. Se permite la inclusión de pacientes con metástasis cerebrales tratadas y estables (esto es, pacientes que no reciben corticoesteroides ni anticonvulsivos, que son estables desde el punto de visto neurológico y que, antes de la aleatorización, llevan al menos 4 semanas sin signos de progresión radiológica). 4. Antecedentes conocidos o presencia de enfermedad leptomeníngea (ELM). 5. Neoplasia maligna invasiva previa o concomitante cuya evolución natural o tratamiento pueda interferir en la evaluación de la seguridad o la eficacia del régimen en investigación 6. Hepatitis activa conocida 7. Cualquier antecedente de infección por el virus de la inmunodeficiencia humana (VIH) 8. Infección conocida por el SARS-CoV-2; podrán participar sujetos con infección previa que se haya resuelto conforme a los requisitos de cada centro y las normas de selección. 9. Cardiopatía clínicamente significativa, como arritmia ventricular que requiera tratamiento, hipertensión no controlada o antecedentes de insuficiencia cardíaca congestiva (ICC) sintomática. 10. QTc según la fórmula de Fridericia (QTcF) > 470 ms. 11. Neuropatía periférica de grado 2 o superior en curso |
|
E.5 End points |
E.5.1 | Primary end point(s) |
●Progression-free survival (PFS) by the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), assessed by blinded independent central review (BICR) ●Overall survival (OS) |
- Supervivencia sin progresión (SSP) conforme a los Criterios de evaluación de la respuesta en tumores sólidos, versión 1.1 (RECIST 1.1), evaluada mediante una revisión central independiente y enmascarada (RCIE). - Supervivencia global (SG) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The primary PFS analysis and interim OS analysis are expected to occur approximately 1 month after the last subject is randomized. The primary analysis of OS is expected to be reached 14 months after the last subject is randomized. |
El análisis principal de la SSP y el análisis intermedio de la SG se espera que ocurra aproximadamente un mes después de la aleatorización del último paciente. Se espera alcanzar el análisis principal de la SG 14 meses después de la aleatorización del último sujeto. |
|
E.5.2 | Secondary end point(s) |
●Confirmed objective response rate (ORR) by RECIST 1.1, assessed by BICR ●Duration of response (DOR) by RECIST 1.1, assessed by BICR ●PFS by RECIST 1.1, per investigator assessment ●ORR by RECIST 1.1, per investigator assessment ●DOR by RECIST 1.1, per investigator assessment ●Frequency, type, severity, seriousness, and relatedness of adverse events (AEs) ●Frequency and severity of clinical laboratory abnormalities ●Change from baseline in health economics and outcomes research / patient-reported outcomes (HEOR/PRO) parameters ●PK parameters for zanidatamab ●PK parameters for tislelizumab ●Frequency, duration, and time of onset of anti zanidatamab antibodies and neutralizing antibodies, if applicable ●Frequency, duration, and time of onset of anti tislelizumab antibodies and neutralizing antibodies, if applicable |
- Tasa de respuestas objetivas (TRO) confirmadas conforme a los criterios RECIST 1.1, según una RCIE. - Duración de la respuesta (DR) evaluada mediante RCIE de acuerdo con los RECIST 1.1 - SSP conforme a los criterios RECIST 1.1, según la evaluación del investigador - TRO conforme a los criterios RECIST 1.1, según la evaluación del investigador - DR conforme a los criterios RECIST 1.1, según la evaluación del investigador - Frecuencia, tipo, intensidad, gravedad y relación de los acontecimientos adversos (AA) - Frecuencia e intensidad de las anomalías analíticas - Variación con respecto al momento basal de los parámetros de economía sanitaria e investigación de resultados/resultados comunicados por los pacientes (ESIR/RCP). - Parámetros FC de zanidatamab - Parámetros FC de tislelizumab - Frecuencia, duración y momento de aparición de los anticuerpos contra zanidatamab y de los anticuerpos neutralizantes, si procede. - Frecuencia, duración y momento de aparición de los anticuerpos contra tislelizimab y de los anticuerpos neutralizantes, si procede. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
The primary PFS analysis and interim OS analysis are expected to occur approximately 1 month after the last subject is randomized. The primary analysis of OS is expected to be reached 14 months after the last subject is randomized. |
El análisis principal de la SSP y el análisis intermedio de la SG se espera que ocurra aproximadamente un mes después de la aleatorización del último paciente. Se espera alcanzar el análisis principal de la SG 14 meses después de la aleatorización del último sujeto. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 12 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 72 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Brazil |
Canada |
Chile |
China |
Korea, Democratic People's Republic of |
Peru |
Russian Federation |
Serbia |
Turkey |
Ukraine |
United States |
Belgium |
France |
Germany |
Italy |
Netherlands |
Poland |
Portugal |
Romania |
Spain |
United Kingdom |
Argentina |
Greece |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS |
Ultima visita del último sujeto |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 8 |